Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis

Bibliography

• Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2):390-2
   PubMed Web of Science ®Google Scholar
• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78
   PubMed Web of Science ®Google Scholar
• Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: education and employment. Rheumatology (Oxford) 2002;41(12):1436-9
   PubMed Web of Science ®Google Scholar
• Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002;41(12):1428-35
   PubMed Web of Science ®Google Scholar
• Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology (Oxford) 2002;41(12):1444-9
   PubMed Web of Science ®Google Scholar
• Foster HE, Marshall N, Myers A, et al. Outcome in adults with juvenile idiopathic arthritis: a quality of life study. Arthritis Rheum 2003;48(3):767-75
   PubMed Web of Science ®Google Scholar
• Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: social function, relationships and sexual activity. Rheumatology (Oxford) 2002;41(12):1440-3
   PubMed Web of Science ®Google Scholar
• Minden K, Niewerth M, Listing J, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46(9):2392-401
   PubMed Web of Science ®Google Scholar
• Beukelman T, Patkar NM, Saag KG, et al. 2011; American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63(4):465-82
   PubMed Web of Science ®Google Scholar
• Gattorno M, Picco P, Buoncompagni A, et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996;55(4):243-7
   PubMed Web of Science ®Google Scholar
• Gattorno M, Picco P, Buoncompagni A, et al. Tumor necrosis factor receptor p75 correlates better than p55 with disease activity in juvenile rheumatoid arthritis: comment on the article by Mangge et al. Arthritis Rheum 1996;39(5):883-4
   PubMed Web of Science ®Google Scholar
• Mangge H, Gallistl S, Schauenstein K. Long-term follow-up of cytokines and soluble cytokine receptors in peripheral blood of patients with juvenile rheumatoid arthritis. J Interferon Cytokine Res 1999;19(9):1005-10
   PubMed Web of Science ®Google Scholar
• Enbrel (package insert). Immunex Corp., Thousand Oaks (CA); 1998 – 2009
   Google Scholar
• Yim DS, Zhou H, Buckwalter M, et al. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005;45(3):246-56
   PubMed Web of Science ®Google Scholar
• Prince FH, Twilt M, Jansen-Wijngaarden NC, van Suijlekom-Smit LW. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis 2007;66(5):704-5
   PubMed Web of Science ®Google Scholar
• Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford, England) 2009;48(8):916-19
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children wiht polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40(7):1202-9
   PubMed Web of Science ®Google Scholar
• Brewer EJ, Bass J, Baum J, et al. Current proposed revision of JRA criteria. Arthritis Rheum 1977;20(Suppl 2):195-9
   PubMedGoogle Scholar
• Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31(11):2290-4
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54(6):1987-94
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58(5):1496-504
   PubMed Web of Science ®Google Scholar
• Ungar WJ, Costa V, Burnett HF, et al. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum 2013;42(6):597-618
   PubMed Web of Science ®Google Scholar
• Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 2013 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Russo RA, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 2002;20(5):723-6
   PubMed Web of Science ®Google Scholar
• Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32(5):935-42
   PubMed Web of Science ®Google Scholar
• Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48(4):1093-101
   PubMed Web of Science ®Google Scholar
• Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68(5):635-41
   PubMed Web of Science ®Google Scholar
• Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005;52(7):2103-8
   PubMed Web of Science ®Google Scholar
• Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004;31(10):2055-61
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FH, Twilt M, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis–data from the dutch arthritis and biologicals in children register, 1999 – 2010. J Rheumatol 2011;38(10):2258-63
   PubMed Web of Science ®Google Scholar
• Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 2009;76(1):24-7
   PubMed Web of Science ®Google Scholar
• Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006;45(8):982-9
   PubMed Web of Science ®Google Scholar
• Tynjala P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66(4):548-50
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J Aapos 2008;12(6):611-13
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013;40(1):74-9
   PubMed Web of Science ®Google Scholar
• Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149(4):572-5
   PubMed Web of Science ®Google Scholar
• Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63(12):1638-44
   PubMed Web of Science ®Google Scholar
• Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68(4):519-25
   PubMed Web of Science ®Google Scholar
• Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford, England) 2011;50(1):189-95
   PubMed Web of Science ®Google Scholar
• Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62(8):2517-24
   PubMed Web of Science ®Google Scholar
• Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64(4):1263-71
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Rosenberg AM, Oen KG, et al. Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol 2011;38(4):760-3
   PubMed Web of Science ®Google Scholar
• Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010;62(12):3776-82
   PubMed Web of Science ®Google Scholar
• Beukelman T, Xie F, Chen L, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64(8):2773-80
   PubMed Web of Science ®Google Scholar
• Beukelman T, Xie F, Baddley JW, et al. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum 2013;65(5):1384-9
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 2010;6(10):561-71
   PubMed Web of Science ®Google Scholar
• Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 2009;30(2):229-38
   PubMed Web of Science ®Google Scholar
• Prince FH, Geerdink LM, Borsboom GJ, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis 2010;69(1):138-42
   PubMed Web of Science ®Google Scholar
• Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26(4):688-92
   PubMed Web of Science ®Google Scholar
• Simonini G, Giani T, Stagi S, et al. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford, England) 2005;44(6):777-80
   PubMed Web of Science ®Google Scholar
• Billiau AD, Loop M, Le PQ, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford, England) 2010;49(8):1550-8
   PubMed Web of Science ®Google Scholar
• Vojvodich PF, Hansen JB, Andersson U, et al. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis. J Rheumatol 2007;34(12):2481-5
   PubMed Web of Science ®Google Scholar
• Prince FH, de Bekker-Grob EW, Twilt M, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Rheumatology (Oxford, England) 2011;50(6):1131-6
   PubMed Web of Science ®Google Scholar
• Burnett HF, Regier DA, Feldman BM, et al. Parents' preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experiment. Arthritis Care Res (Hoboken) 2012;64(9):1382-91
   PubMed Web of Science ®Google Scholar
• Ringold S, Grant S, Girdish C, et al. Injectable tumor necrosis alpha factor inhibitors and outpatient antimicrobial use in children with rheumatic diseases: analyses of prescription claims from a pharmacy benefit manager. Arthritis Care Res (Hoboken) 2013 [Epub ahead of print]
   Web of Science ®Google Scholar
• Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003;48(7):1771-4
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64(6):2012-21
   PubMed Web of Science ®Google Scholar
• Anink J, Otten MH, Gorter SL, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology (Oxford) 2013;52(9):1674-9
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306(21):2340-7
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63(2):545-55
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367(25):2385-95
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367(25):2396-406
   PubMed Web of Science ®Google Scholar
• Prince FH, Twilt M, Simon SC, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2009;68(7):1228-9
   PubMed Web of Science ®Google Scholar
• Martini A, Lovell DJ. Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis 2010;69(7):1260-3
   PubMed Web of Science ®Google Scholar
• Hunter PJ, Wedderburn LR. Pediatric rheumatic disease: can molecular profiling predict the future in JIA? Nat Rev Rheumatol 2009;5(11):593-4
   PubMed Web of Science ®Google Scholar
• Ruperto N, Giannini EH, Pistorio A, et al. Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs. Arthritis Rheum 2010;62(11):3131-9
   PubMed Web of Science ®Google Scholar
• Abrahamyan L, Beyene J, Feng J, et al. Response times follow lognormal or gamma distribution in arthritis patients. J Clin Epidemiol 2010;63(12):1363-9
   PubMed Web of Science ®Google Scholar
• Leblanc CM, Lang B, Bencivenga A, et al. Access to biologic therapies in Canada for children with juvenile idiopathic arthritis. J Rheumatol 2012;39(9):1875-9
   PubMed Web of Science ®Google Scholar